Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Kapiloff earned his Ph.D. in Biomedical Sciences in 1991 at the University of California, San Diego, in the laboratory of Dr. M. Geoffrey Rosenfeld, a HHMI investigator and member of the National Academy of Sciences. He graduated from UCSD with a Doctorate of Medicine in 1992 and completed a residency in General Pediatrics at the University of Utah in 1995. In 1997, Dr. Kapiloff became a Research Assistant Professor, performing research in the laboratory of HHMI Investigator Dr. John Scott at the Vollum Institute in Portland, OR. From 1999 to 2007, Dr. Kapiloff was an Assistant Professor of Pediatrics at the Oregon Health and Science University in Portland. From 2007 to 2017, he was Director of the Cardiac Signal Transduction and Cellular Biology Laboratory at the University of Miami Miller School of Medicine in Miami, Florida, where he was, as of 2013, a tenured Professor of Pediatrics and Medicine in the Division of Cardiology. Since 2011, Dr. Kapiloff has also been studying signal transduction pathways in the eye. Dr. Kapiloff was recruited to Stanford in July, 2017 in a joint effort by the Department of Ophthalmology and the Stanford Cardiovascular Institute in recognition of his work in both fields.
Dr. Michael S. Kapiloff is a faculty member in the Departments of Ophthalmology and Medicine (Cardiovascular Medicine) and a member of the Stanford Cardiovascular Institute. Although Dr. Kapiloff was at one time a Board-Certified General Pediatrician, he is currently involved in full-time basic science and translational research. His laboratory studies the basic molecular mechanisms underlying the response of the retinal ganglion cell and cardiac myocyte to disease. The longstanding interest of his laboratory is the role in intracellular signal transduction of multimolecular complexes organized by scaffold proteins. Recently, his lab has also been involved in the translation of these concepts into new therapies, including the development of new AAV gene therapy biologics for the prevention and treatment of heart failure and for neuroprotection in the eye.URL to NCBI listing of all published works:http://www.ncbi.nlm.nih.gov/sites/myncbi/michael.kapiloff.1/bibliography/40252285/public/?sort=date&direction=descendingFor more information see Dr. Kapiloff's lab website: http://med.stanford.edu/kapilofflab.html